Expand AGEN Menu
AGEN MENU

AGEN Latest Press Releases

-- March 17, 2026 --

Agenus Announces Upcoming AACR 2026 Presentation Evaluating Botensilimab Plus Balstilimab in First-Line MSS Metastatic Colorectal Cancer Business Wire 4:40 PM

-- March 16, 2026 --

Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized Business Wire 7:30 AM

-- March 10, 2026 --

Agenus Triggers First $20M Contingent Payment Under Zydus Life Sciences Collaboration to Support BOT+BAL Manufacturing Needs Business Wire 7:30 AM

-- March 4, 2026 --

Agenus to Provide Fourth Quarter and Year-end 2025 Financial Report and Corporate Update Business Wire 4:30 PM

-- February 19, 2026 --

Agenus Presents Biomarker Data Demonstrating Survival Stratification in MSS mCRC and Other Immunologically Cold Tumors Treated with BOT+BAL Business Wire 3:15 PM

-- February 9, 2026 --

Agenus to Present New Data at AACR-IO Exploring Systemic and Tumor Inflammation Biomarkers with BOT/BAL in Immunologically Cold Tumors Business Wire 1:00 PM

-- January 21, 2026 --

Agenus Expands Medical Affairs Infrastructure to Support Increasing Physician Requests for Authorized Access to Botensilimab Plus Balstilimab Business Wire 7:30 AM

-- January 20, 2026 --

Agenus to Host First 2026 Stakeholder Webcast Business Wire 6:24 PM

-- January 15, 2026 --

Zydus Lifesciences Limited completes the acquisition of Agenus Inc.'s biologics manufacturing facilities, launches Zylidac Bio LLC in the U.S. PRNewswire 8:31 AM
Agenus Announces Closing of $141M Strategic Collaboration with Zydus Lifesciences to Advance BOT+BAL and Strengthen U.S. Manufacturing Readiness Business Wire 7:01 AM

-- January 12, 2026 --

France Expands National AAC Access for Agenus' Botensilimab + Balstilimab for Ovarian Cancer and Soft-Tissue Sarcomas Business Wire 7:30 AM

-- December 23, 2025 --

Agenus Reports Deep, Durable Responses with Botensilimab + Balstilimab in Highly Refractory Ovarian Cancer, Published in JITC Business Wire 8:05 AM

-- December 12, 2025 --

GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era Globe Newswire 10:31 AM

-- November 19, 2025 --

Agenus to Host End-of-Year Stakeholder Webcast Featuring GI Oncology Leaders and Progress of BOT/BAL Business Wire 4:01 PM

-- November 18, 2025 --

Agenus Appoints Dr. Jos Iglesias as Chief Medical Affairs Officer to Guide Global Medical Affairs and Early-Access Programs, Including France's AAC Business Wire 8:41 AM

-- November 10, 2025 --

Agenus Reports Q3 2025 Results Showcasing Clinical and Regulatory Advances Business Wire 7:30 AM

-- November 5, 2025 --

Agenus to Provide Corporate Update and Third Quarter 2025 Financial Report Business Wire 1:47 PM
Market Data Delayed 15 Minutes